+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015

  • ID: 3293079
  • Report
  • May 2015
  • 175 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Assessment by Target
  • Forward Pharma A/S
  • Mapi Pharma Ltd.
  • Novartis AG
  • RedHill Biopharma Ltd.
  • MORE
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015

Summary

This, ‘Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015’, provides an overview of the Relapsing Remitting Multiple Sclerosis (RRMS)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Relapsing Remitting Multiple Sclerosis (RRMS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Assessment by Target
  • Forward Pharma A/S
  • Mapi Pharma Ltd.
  • Novartis AG
  • RedHill Biopharma Ltd.
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Relapsing Remitting Multiple Sclerosis (RRMS) Overview
Therapeutics Development
Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Overview
Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis
Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Development by Companies
Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Investigation by Universities/Institutes
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Development by Companies
Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Investigation by Universities/Institutes
Relapsing Remitting Multiple Sclerosis (RRMS) - Companies Involved in Therapeutics Development
AbbVie Inc.
Actelion Ltd
Allozyne, Inc.
Amarna Therapeutics B.V.
Antisense Therapeutics Limited
Biogen, Inc.
Cognosci, Inc.
F. Hoffmann-La Roche Ltd.
Forward Pharma A/S
Genmab A/S
GlaxoSmithKline plc
Iltoo Pharma
Mapi Pharma Ltd.
MedImmune, LLC
Merck KGaA
Mitsubishi Tanabe Pharma Corporation
Neurotec Pharma SL
Novartis AG
Nuron Biotech, Inc.
Octapharma AG
Opexa Therapeutics, Inc.
RedHill Biopharma Ltd.
Sanofi
Synthetic Biologics, Inc.
Teva Pharmaceutical Industries Limited
XenoPort, Inc.
Zydus Cadila Healthcare Limited
Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(rifabutin + clarithromycin + clofazimine) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aldesleukin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATL-1102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATXMS-1467 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZ-17 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for Relapsing Remitting Multiple Sclerosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
COG-133 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
daclizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diazoxide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dimethyl fumarate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
estriol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Relapsing and Remitting Multiple Sclerosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
glatiramer acetate ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-239512 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Guanabenz - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HR-411 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
hydralazine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
imilecleucel-t - Drug Profile
Product Description
Mechanism of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon beta-1b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon beta-1b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon beta-1b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
laquinimod sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MEDI-551 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MT-1303 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ofatumumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
olesoxime - Drug Profile
Product Description
Mechanism of Action
R&D Progress
opicinumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pegylated Interferon-Beta-1b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ponesimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
siponimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Target CTLA4 and IFNGR for RRMS - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vatelizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VAY-736 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XP-23829 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Relapsing Remitting Multiple Sclerosis (RRMS) - Recent Pipeline Updates
Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects
Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products
Relapsing Remitting Multiple Sclerosis (RRMS) - Product Development Milestones
Featured News & Press Releases
Feb 26, 2015: Abbvie's Ongoing Research In Neuroscience And Oncology On ZINBRYTA Will Be Featured At The 2015 American Academy Of Neurology Annual Meeting
Dec 17, 2014: First Patient Treated in Mapi Pharma's Phase IIa Clinical Trial of GA Depot for Relapsing Remitting Multiple Sclerosis
Nov 04, 2014: Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis
Sep 12, 2014: Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA (Daclizumab High-Yield Process)
Sep 12, 2014: Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting
Jul 31, 2014: Expanded Data on Disability and Cognitive Improvements in Phase II Study of Synthetic Biologics' Trimesta in Multiple Sclerosis to be Presented at 2014 Joint ACTRIMS-ECTRIMS Meeting
May 30, 2014: Genmab Announces Ofatumumab Development Plans in RRMS and NMO
May 23, 2014: Teva and Active Biotech to Continue with the Development of Nerventra for Multiple Sclerosis Following Confirmation of CHMP Opinion
Apr 29, 2014: Synthetic Biologics Reports University of California, Los Angeles Announcement Of Preliminary Positive Topline Efficacy And Safety Results From Investigator-Led Phase 2 Study Of Trimesta For Relapsing-Remitting Multiple Sclerosis
Apr 07, 2014: ATL1102 for MS - US Patent Allowance Extends Strong IP Position
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS), H1 2015
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by AbbVie Inc., H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Actelion Ltd, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Allozyne, Inc., H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Amarna Therapeutics B.V., H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Antisense Therapeutics Limited, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Biogen, Inc., H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Cognosci, Inc., H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Forward Pharma A/S, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Genmab A/S, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by GlaxoSmithKline plc, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Iltoo Pharma, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Mapi Pharma Ltd., H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by MedImmune, LLC, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Merck KGaA, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Neurotec Pharma SL, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Novartis AG, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Nuron Biotech, Inc., H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Octapharma AG, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Opexa Therapeutics, Inc., H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by RedHill Biopharma Ltd., H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Sanofi, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Synthetic Biologics, Inc., H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by XenoPort, Inc., H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Zydus Cadila Healthcare Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics - Recent Pipeline Updates, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects (Contd..1), H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects (Contd..2), H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products (Contd..1), H1 2015

List of Figures
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS), H1 2015
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
4 of 5
AbbVie Inc.
Actelion Ltd
Allozyne, Inc.
Amarna Therapeutics B.V.
Antisense Therapeutics Limited
Biogen, Inc.
Cognosci, Inc.
F. Hoffmann-La Roche Ltd.
Forward Pharma A/S
Genmab A/S
GlaxoSmithKline plc
Iltoo Pharma
Mapi Pharma Ltd.
MedImmune, LLC
Merck KGaA
Mitsubishi Tanabe Pharma Corporation
Neurotec Pharma SL
Novartis AG
Nuron Biotech, Inc.
Octapharma AG
Opexa Therapeutics, Inc.
RedHill Biopharma Ltd.
Sanofi
Synthetic Biologics, Inc.
Teva Pharmaceutical Industries Limited
XenoPort, Inc.
Zydus Cadila Healthcare Limited
lapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics Asses
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll